A Study to Investigate LYL797 in Adults With Solid Tumors

Overview

Información sobre este estudio

The purpose of this study is to evaluate the safety and tolerability of LYL797, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC) or non-small cell lung cancer (NSCLC). The first part of the study will determine the safe dose for the next part of the study, and will enroll TNBC patients only. The second part of the study will test that dose in additional TNBC patients and NSCLC patients.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

- ≥ 18 years of age at time of informed consent

- Histologically confirmed TNBC or NSCLC that is relapsed or refractory, metastatic or
locally advanced and unresectable that is ROR1+ by central laboratory
immunohistochemistry (IHC)

- Measurable disease including a target lesion and an additional lesion for biopsy

- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

- Adequate organ and marrow function

- Women of childbearing potential must have a negative pregnancy test at screening

- All participants must agree to practice highly effective methods of contraception

Exclusion Criteria:

- Prior treatment with any adoptive T-cell therapy or anti-ROR1 therapy

- Prior solid organ transplantation

- Active, untreated brain metastasis or leptomeningeal disease; stable, treated brain
involvement by disease is allowed

- Untreated or active infection at the time of screening or leukapheresis

- HIV-positive, HTLV-1-positive, active acute or chronic HBV or HCV, or active
tuberculosis

- Impaired cardiac function or clinically significant cardiac disease

- Uncontrolled pleural or pericardial effusion

- Systemic corticosteroids or other immunosuppressive medications within 14 days of
leukapheresis

- Required chronic anticoagulation, such as warfarin, low molecular weight heparin, or
Factor Xa inhibitors

- Pregnant or lactating/nursing women

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 5/4/23. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Roberto Leon Ferre, M.D.

Abierto para la inscripción

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Jacksonville, Fla.

Investigador principal de Mayo Clinic

Hemant Murthy, M.D.

Abierto para la inscripción

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Scottsdale/Phoenix, Ariz.

Investigador principal de Mayo Clinic

Brenda Ernst, M.D.

Abierto para la inscripción

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publicaciones

Publications are currently not available
.
CLS-20537302

Mayo Clinic Footer